Research Paper Volume 14, Issue 11 pp 4839—4857
Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
Figure 2. Immune-response prediction by Tumor Immune Dysfunction and Exclusion (TIDE). (A) Patients were predicted to be responders/non-responders to immunotherapy based on the TIDE score. (B) The score for immune features of TIDE score, Dysfunction, Exclusion, MDSC, CAF, and TAM predicted by TIDE. (C) The score for immune features of IFNG, MSI, Merck18, CD274, and CD8. Asterisks indicate the level of statistical significance: * < 0.05; ** < 0.01; *** < 0.001; and **** < 0.0001.